By CLAUDIA CHIAPPA with DOMINIC GIANNINI and EMMA PIRNAY SNEAK PEEK The cyber resilience of Europe’s health systems is under the spotlight after an attack on French refrigerators raises concern about vaccine vulnerabilities. Health payers and patient groups want a new EU-funded tool to ensure innovative medicines remain affordable amid U.S. pricing pressures. The European […]
Read More
Read original article on New African UK-based pharmaceutical company Stablepharma is preparing for a pivotal Phase 2b clinical trial of ‘SPVX02’, its thermostable version of an existing tetanus-diphtheria vaccine, following the success of a Phase 1 clinical trial. Unlike conventional vaccines which become unusable after a few hours or days out of the fridge, ‘SPVX02’ […]
Read More
Read original article on BMJ.com A tetanus-diphtheria vaccine that can be stored at room temperature has shown promising early results in a development hailed as a potential “game changer” for global health. Maintaining the cold chain for vaccines is a significant challenge in resource poor countries, remote communities, and regions affected by conflict. About half […]
Read More
Read original article on bbc.co.uk Vaccines that do not need to be kept cool in a fridge have been successfully trialled in patients for the first time, say UK scientists. Currently, most vaccines need to be refrigerated or frozen – but around half are wasted each year, mainly because they become unusable after getting too […]
Read More Potential agreement follows positive clinical and stability data, supporting rollout in UK, Canada, Australia and New Zealand London, UK – June 15, 2026 Stablepharma Limited, specialists in thermostable formulations, today announced the signing of a Letter of Intent (LOI) with AFT Pharmaceuticals (NZX: AFT; ASX: AFP) regarding the proposed distribution of SPVX02, their lead fridge-free […]
Read More
London, UK – 15 January 2026 – Stablepharma Limited, specialists in thermostable formulations, today announced a development and option-to-license agreement with AFT Pharmaceuticals to develop a portfolio of fridge-free sterile injectable medicines, initially targeting anti-infective and oncology treatments in a total global market valued at over USD 6 billion. Stablepharma will apply its proprietary stabilisation […]
Read More London, UK – 03 November 2025 – Stablepharma announced the database lock of its Phase 1 clinical trial of the world’s first, fridge-free, tetanus-diphtheria vaccine, SPVX02, which began recruitment in April this year. The trial evaluated the safety, tolerability and immunogenicity of SPVX02 against 2 comparator vaccines and enrolled 60 healthy participants at 2 UK […]
Read More
click here to read full article
Read More
Following MHRA approval, Stablepharma Ltd has commenced a Phase 1 clinical trial with its lead candidate, fridge-free tetanus and diphtheria vaccine, SPVX02. The Phase 1, first-in-human clinical trial led by Professor Saul Faust, is being conducted at the National Institute for Health and Care Research (NIHR) at Southampton Clinical Research Facility. Stablepharma’s pioneering science has […]
Read More